{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T18:21:30Z","timestamp":1755800490884},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2011,7,7]],"date-time":"2011-07-07T00:00:00Z","timestamp":1309996800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1007\/s00404-011-1976-9","type":"journal-article","created":{"date-parts":[[2011,7,6]],"date-time":"2011-07-06T13:07:02Z","timestamp":1309957622000},"page":"499-503","source":"Crossref","is-referenced-by-count":1,"title":["Weekly paclitaxel in heavily pretreated ovarian cancer patients: does this treatment still provide further advantages?"],"prefix":"10.1007","volume":"285","author":[{"given":"GianMaria","family":"Miolo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ettore","family":"Bidoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide Adriano","family":"Santeufemia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giampiero","family":"Capobianco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Dessole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Scalone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Spazzapan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Sorio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianna","family":"Tabaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Veronesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,7,7]]},"reference":[{"key":"1976_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","volume":"334","author":"WP McGuire","year":"1996","unstructured":"McGuire WP, Hoskins WJ, Brady MF et al (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1\u20136","journal-title":"N Engl J Med"},{"key":"1976_CR2","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/jnci\/92.9.699","volume":"92","author":"MJ Piccart","year":"2000","unstructured":"Piccart MJ, Bertelsen K, James K et al (2000) Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 92:699\u2013708","journal-title":"J Natl Cancer Inst"},{"issue":"Suppl","key":"1976_CR3","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1634\/theoncologist.6-suppl_3-30","volume":"3","author":"L Norton","year":"2001","unstructured":"Norton L (2001) Theoretical concepts and the emerging role of taxanes in adjuvant therapy. Oncologist 3(Suppl):30\u201335","journal-title":"Oncologist"},{"key":"1976_CR4","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S0140-6736(09)61157-0","volume":"374","author":"N Katsumata","year":"2009","unstructured":"Katsumata N, Yasuda M, Takahashi F et al (2009) Japanese Gynecologic Oncology Group. Dose-dense paclitaxel once a week in combination with carboplatin every 3\u00a0weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 374:1331\u20131338","journal-title":"Lancet"},{"issue":"Suppl","key":"1976_CR5","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/S1040-8428(02)00103-8","volume":"44","author":"H Thomas","year":"2002","unstructured":"Thomas H, Rosenberg P (2002) Role of weekly paclitaxel in the treatment of advanced ovarian cancer. Crit Rev Oncol Hematol 44(Suppl):S43\u2013S51","journal-title":"Crit Rev Oncol Hematol"},{"key":"1976_CR6","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1200\/JCO.2002.09.130","volume":"20","author":"M Markman","year":"2002","unstructured":"Markman M, Hall J, Spitz D et al (2002) Phase II trial of weekly single-agent Paclitaxel in platinum\/Paclitaxel-refractory ovarian cancer. J Clin Oncol 20:2365\u20132369","journal-title":"J Clin Oncol"},{"key":"1976_CR7","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ygyno.2005.11.025","volume":"102","author":"T Le","year":"2006","unstructured":"Le T, Hopkins L, Baines KA et al (2006) Prospective evaluations of continuous weekly paclitaxel regimen in recurrent platinum-resistant epithelial ovarian cancer. Gynecol Oncol 102:49\u201353","journal-title":"Gynecol Oncol"},{"key":"1976_CR8","first-page":"383","volume":"23","author":"J Kaern","year":"2002","unstructured":"Kaern J, Baekelandt M, Trope CG (2002) A phase II study of weekly paclitaxel in platinum and Paclitaxel-resistant ovarian cancer patients. Eur J Gynaecol Oncol 23:383\u2013389","journal-title":"Eur J Gynaecol Oncol"},{"key":"1976_CR9","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ygyno.2008.01.007","volume":"109","author":"M Linch","year":"2008","unstructured":"Linch M, Stavridi F, Hook J et al (2008) Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer. Gynecol Oncol 109:27\u201332","journal-title":"Gynecol Oncol"},{"key":"1976_CR10","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1046\/j.1525-1438.2003.13045.x","volume":"13","author":"S Ghamande","year":"2003","unstructured":"Ghamande S, Lele S, Marchetti D et al (2003) Weekly paclitaxel in patients with recurrent or persistent advanced ovarian cancer. Int J Gynecol Cancer 13:142\u2013147","journal-title":"Int J Gynecol Cancer"},{"key":"1976_CR11","first-page":"a568","volume":"16","author":"S Breier","year":"1997","unstructured":"Breier S, Lebedinsky C, Pelayes L et al (1997) Phase I\/II weekly paclitaxel (P) 80\u00a0mg\/m2 in pretreated patients (pts) with breast (BC) and ovarian cancer (OC) [abstract]. Proc Am Soc Clin Oncol 16:a568","journal-title":"Proc Am Soc Clin Oncol"},{"key":"1976_CR12","first-page":"2506","volume":"20","author":"C Thirapakawong","year":"2001","unstructured":"Thirapakawong C, Senapad S, Pedangsutt P et al (2001) Phase II study of weekly paclitaxel (Taxol) as a second line chemotherapy in refractory epithelial ovarian cancer (EOC): a multicenter study. Pro Am Soc Clin Oncol 20:2506 (abstract)","journal-title":"Pro Am Soc Clin Oncol"},{"key":"1976_CR13","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1200\/JCO.1997.15.1.187","volume":"15","author":"D Fennelly","year":"1997","unstructured":"Fennelly D, Aghajanian C, Shapiro F et al (1997) Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 15:187\u2013192","journal-title":"J Clin Oncol"},{"key":"1976_CR14","first-page":"32","volume":"23","author":"TM L\u00f6ffler","year":"1996","unstructured":"L\u00f6ffler TM, Freund W, Lipke J et al (1996) Schedule- and dose-intensified paclitaxel as weekly 1-hour infusion in pretreated solid tumors: results of a phase I\/II trial. Semin Oncol 23:32\u201334","journal-title":"Semin Oncol"},{"key":"1976_CR15","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/0959-8049(95)00641-9","volume":"32","author":"U Klaassen","year":"1996","unstructured":"Klaassen U, Wilke H, Strumberg D et al (1996) Phase I study with a weekly 1\u00a0h infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancer. Eur J Cancer 32:547\u2013549","journal-title":"Eur J Cancer"},{"key":"1976_CR16","first-page":"79","volume":"26","author":"I Dunder","year":"2005","unstructured":"Dunder I, Berker B, Atabekoglu C et al (2005) Preliminary experience with salvage weekly paclitaxel in women with advanced recurrent ovarian carcinoma. Eur J Gynaecol Oncol 26:79\u201382","journal-title":"Eur J Gynaecol Oncol"},{"key":"1976_CR17","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.ygyno.2003.12.002","volume":"92","author":"T Kita","year":"2004","unstructured":"Kita T, Kikuchi Y, Takano M et al (2004) The effect of single weekly paclitaxel in heavily pretreated patients with recurrent or persistent advanced ovarian cancer. Gynecol Oncol 92:813\u2013818","journal-title":"Gynecol Oncol"},{"key":"1976_CR18","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1080\/028418602320404998","volume":"41","author":"P Rosenberg","year":"2002","unstructured":"Rosenberg P, Andersson H, Boman K et al (2002) Randomized trial of single agent Paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncol 41:418\u2013424","journal-title":"Acta Oncol"},{"key":"1976_CR19","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1525-1438.2007.00990.x","volume":"18","author":"A Molckowsky","year":"2008","unstructured":"Molckowsky A, Vijay SM, Hopman WM et al (2008) Decreased dose density of standard chemotherapy does not compromise survival for ovarian cancer patients. Int J Gynecol Cancer 18:8\u201313","journal-title":"Int J Gynecol Cancer"},{"key":"1976_CR20","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ijc.10907","volume":"104","author":"DS Grant","year":"2003","unstructured":"Grant DS, Williams TL, Iliakis G et al (2003) Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere). Int J Cancer 104:121\u2013129","journal-title":"Int J Cancer"},{"key":"1976_CR21","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1158\/1535-7163.1301.3.10","volume":"3","author":"E Pasquier","year":"2004","unstructured":"Pasquier E, Carr\u00e8 M, Pourroy B et al (2004) Antiangiogenic activity of paclitaxel is associated with its cytostatic effect, mediated by the initiation but not completion of a mitochondrial apoptotic signaling pathway. Mol Cancer Ther 3:1301\u20131310","journal-title":"Mol Cancer Ther"},{"key":"1976_CR22","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1158\/0008-5472.CAN-04-2624","volume":"65","author":"E Pasquier","year":"2005","unstructured":"Pasquier E, Honore S, Pourroy B et al (2005) Antiangiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells. Cancer Res 65:2433\u20132440","journal-title":"Cancer Res"},{"key":"1976_CR23","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nrc1369","volume":"4","author":"RS Kerbel","year":"2004","unstructured":"Kerbel RS, Kamen BA (2004) The antiangiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4:423\u2013436","journal-title":"Nat Rev Cancer"},{"key":"1976_CR24","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ygyno.2004.03.044","volume":"94","author":"X Zhijung","year":"2004","unstructured":"Zhijung X, Kaern J, Davidson B et al (2004) Kallikrein 4 is associated with paclitaxel resistance in ovarian cancer. Ginecol Oncol 94:80\u201385","journal-title":"Ginecol Oncol"},{"key":"1976_CR25","first-page":"2363","volume":"7","author":"Y Dong","year":"2001","unstructured":"Dong Y, Kaushal A, Bui L et al (2001) Human kallikrein 4 (KLK4) is highly expressed in serous ovarian carcinomas. Clin Cancer Res 7:2363\u20132371","journal-title":"Clin Cancer Res"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-011-1976-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00404-011-1976-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-011-1976-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T00:56:38Z","timestamp":1686185798000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00404-011-1976-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7,7]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["1976"],"URL":"https:\/\/doi.org\/10.1007\/s00404-011-1976-9","relation":{},"ISSN":["0932-0067","1432-0711"],"issn-type":[{"value":"0932-0067","type":"print"},{"value":"1432-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7,7]]}}}